for the past three years. Patient's Mini-Mental Status Examination (MMSE) is 24; she is fully oriented; handles problems with moderate difficulty; experiences mild but definite impairment functioning at home; and requires assistance to function independently in community affairs. She denies history of strokes, seizures and family history of memory difficulties.
Patient admits to a previously failed prescription AD drug for 6 months followed by a participation in a separate investigational drug study for memory loss more than two years before commencing the current study. Any ongoing medications including over-the-counter medications, vitamin and herbal supplements were reviewed to have no interactions with the study drug or to suspect to cause serious adverse effects before granting admission to the study.
Immediately right after the AE report, a full physical exam and neurological exam was performed by a study doctor. Results were all within normal range. There was no loss of consciousness (LOC), confusion, bladder incontinence, rigidity of the limbs, vertigo, abnormal gait or cranial nerve (CN) functions, motor and sensory abnormalities, headaches, seizures or residual tremors. Most recent Magnetic Resonance Imaging (MRI) report mentions stable cerebral atrophy and age-related changes, consistent with other MRI reports in comparison to the previous years.
The case of full-body tremors is a case of unknown etiology. Patient was referred to a neurologist for further consultation and shortly thereafter, she opted for an early termination from further participation and cessation of the study drug. A follow-up phone call a few Introduction Full-body tremors was not a known or a documented adverse effect (AE) in an investigational drug for prodromal Alzheimer's disease (AD) that reduces beta-amyloid plaques, proteins that may be involved in causing AD.
Case Description
A 69-year-old Caucasian female experienced multiple episodes of full-body tremors during the extension phase of the clinical study. The investigational drug was taken in the mornings. The patient reported that the AE started six months prior with episodes occurring 1-2 times per week eventually escalating almost daily and was more apparent during midnight hours and upon waking up. Further review of progress notes states that the patient denied the AE and even stated full compliance and no complaints as per protocol before admitting to three missed doses later on.
Patient and trial partner were informed accordingly and in return provided consents acknowledging the risks, the benefits and their roles throughout the entire duration of the study after satisfying the eligibility study criteria. Concomitant medical review, clinical and cognitive assessment scales as well as urinalysis, blood sampling, dermatological exam, monitoring for dementia progression and +/-brain imaging were conducted during her clinical study screening visit and the subsequent clinical study visits. Patient and trial partner were encouraged to report any AE, discomfort, missed doses or any concerns.
Her medical history reveals gradual memory decline, most notably forgetfulness of words and conversations
